A first case of ‘Covid toes’ from a viral vector-based COVID-19 vaccine
A. Van Loon
Department of Dermatology, University Hospital Antwerp (UZA) and Research Group Immunology, Infla-Med Centre of Excellence, University of Antwerp, Antwerp, Belgium
Search for more papers by this authorD. Mortelmans
Department of Dermatology, University Hospital Antwerp (UZA) and Research Group Immunology, Infla-Med Centre of Excellence, University of Antwerp, Antwerp, Belgium
Search for more papers by this authorV. Siozopoulou
Department of Pathology, University Hospital Antwerp (UZA) and University of Antwerp, Antwerp, Belgium
Search for more papers by this authorB. Ogunjimi
Department of Pediatrics, University Hospital Antwerp (UZA) and University of Antwerp, Antwerp, Belgium
Search for more papers by this authorH. Jansens
Department of Laboratory Medicine, University Hospital Antwerp (UZA) and University of Antwerp, Antwerp, Belgium
Search for more papers by this authorJ. Lambert
Department of Dermatology, University Hospital Antwerp (UZA) and Research Group Immunology, Infla-Med Centre of Excellence, University of Antwerp, Antwerp, Belgium
Search for more papers by this authorCorresponding Author
O. Aerts
Department of Dermatology, University Hospital Antwerp (UZA) and Research Group Immunology, Infla-Med Centre of Excellence, University of Antwerp, Antwerp, Belgium
*Correspondence: O. Aerts. E-mail: [email protected]
Search for more papers by this authorA. Van Loon
Department of Dermatology, University Hospital Antwerp (UZA) and Research Group Immunology, Infla-Med Centre of Excellence, University of Antwerp, Antwerp, Belgium
Search for more papers by this authorD. Mortelmans
Department of Dermatology, University Hospital Antwerp (UZA) and Research Group Immunology, Infla-Med Centre of Excellence, University of Antwerp, Antwerp, Belgium
Search for more papers by this authorV. Siozopoulou
Department of Pathology, University Hospital Antwerp (UZA) and University of Antwerp, Antwerp, Belgium
Search for more papers by this authorB. Ogunjimi
Department of Pediatrics, University Hospital Antwerp (UZA) and University of Antwerp, Antwerp, Belgium
Search for more papers by this authorH. Jansens
Department of Laboratory Medicine, University Hospital Antwerp (UZA) and University of Antwerp, Antwerp, Belgium
Search for more papers by this authorJ. Lambert
Department of Dermatology, University Hospital Antwerp (UZA) and Research Group Immunology, Infla-Med Centre of Excellence, University of Antwerp, Antwerp, Belgium
Search for more papers by this authorCorresponding Author
O. Aerts
Department of Dermatology, University Hospital Antwerp (UZA) and Research Group Immunology, Infla-Med Centre of Excellence, University of Antwerp, Antwerp, Belgium
*Correspondence: O. Aerts. E-mail: [email protected]
Search for more papers by this authorConflicts of interest
None to declare.
Open Research
Data availability statement
Data available on request.
References
- 1Galván Casas C, Català A, Carretero Hernández G et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol 2020; 183: 71–77.
- 2Herman A, Peeters C, Verroken A et al. Evaluation of chilblains as a manifestation of the COVID-19 pandemic. JAMA Dermatol 2020; 156: 998–1003.
- 3McMahon DE, Amerson E, Rosenbach M et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases. J Am Acad Dermatol 2021; 85: 46–55.
- 4Meara AS, Silkoski M, Quin K, Jarjour W. A case of chilblains-like lesions post SARS-CoV-2 vaccine? J Rheumatol 2021; 48: 1754.
- 5Kelso JM, Coda AB, Keating RM, Vaccari DM. "COVID Toes" after mRNA COVID-19 vaccines. J Allergy Clin Immunol Pract 2021; 9: 3196–3197.
- 6Lesort C, Kanitakis J, Donzier L, Jullien D. Chilblain-like lesions after BNT162b2 mRNA COVID-19 vaccine: a case report suggesting that 'COVID toes' are due to the immune reaction to SARS-CoV-2. J Eur Acad Dermatol Venereol 2021; 35: https://doi.org/10.1111/jdv.17451.
- 7Davido B, Mascitti H, Fortier-Beaulieu M, Jaffal K, de Truchis P. 'Blue toes' following vaccination with the BNT162b2 mRNA COVID-19 vaccine. J Travel Med 2021; 28: taab024.
- 8Holmes GA, Desai M, Limone B et al. A Case series of cutaneous COVID-19 vaccine reactions at Loma Linda university department of dermatology. JAAD Case Reports 2021; 16: 53–57.
- 9Piccolo V, Bassi A, Argenziano G et al. BNT162b2 mRNA COVID-19 vaccine-induced chilblain-like lesions reinforces the hypothesis of their relationship with SARS-CoV-2. J Eur Acad Dermatol Venereol 2021; 35: e493–e494.
- 10Temiz SA, Abdelmaksoud A, Dursun R, Vestita M. Acral chilblain-like lesions following inactivated SARS-CoV-2 vaccination. Int J Dermatol 2021; 60: 1152–1153.
Citing Literature
